DE60024664T2 - Verfahren zur identifizierung von verbindungen, die die neuronale aktivität modulieren - Google Patents
Verfahren zur identifizierung von verbindungen, die die neuronale aktivität modulieren Download PDFInfo
- Publication number
- DE60024664T2 DE60024664T2 DE60024664T DE60024664T DE60024664T2 DE 60024664 T2 DE60024664 T2 DE 60024664T2 DE 60024664 T DE60024664 T DE 60024664T DE 60024664 T DE60024664 T DE 60024664T DE 60024664 T2 DE60024664 T2 DE 60024664T2
- Authority
- DE
- Germany
- Prior art keywords
- peptide
- plmf
- sequence
- amino acids
- downstream
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 25
- 238000000034 method Methods 0.000 title claims description 17
- 230000001537 neural effect Effects 0.000 title description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 47
- 230000014509 gene expression Effects 0.000 claims abstract description 20
- 108090000312 Calcium Channels Proteins 0.000 claims abstract description 14
- 102000003922 Calcium Channels Human genes 0.000 claims abstract description 14
- 102000004310 Ion Channels Human genes 0.000 claims abstract description 11
- 108090000862 Ion Channels Proteins 0.000 claims abstract description 11
- 102000010029 Homer Scaffolding Proteins Human genes 0.000 claims abstract description 9
- 108010077223 Homer Scaffolding Proteins Proteins 0.000 claims abstract description 9
- 210000004899 c-terminal region Anatomy 0.000 claims abstract description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 3
- 210000004027 cell Anatomy 0.000 claims description 23
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 238000011144 upstream manufacturing Methods 0.000 claims description 11
- 239000003446 ligand Substances 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 238000003259 recombinant expression Methods 0.000 claims 2
- 230000028252 learning or memory Effects 0.000 claims 1
- 108010090618 Syntaxin 1 Proteins 0.000 abstract description 28
- 102000013265 Syntaxin 1 Human genes 0.000 abstract description 27
- 210000003169 central nervous system Anatomy 0.000 abstract description 11
- 108090000623 proteins and genes Proteins 0.000 abstract description 9
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 4
- 238000007423 screening assay Methods 0.000 abstract 1
- 108091006146 Channels Proteins 0.000 description 11
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 10
- 229910052791 calcium Inorganic materials 0.000 description 10
- 239000011575 calcium Substances 0.000 description 10
- 230000003834 intracellular effect Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 8
- 229910001424 calcium ion Inorganic materials 0.000 description 8
- 108700012358 P/Q-type calcium channel Proteins 0.000 description 7
- 102000050761 P/Q-type calcium channel Human genes 0.000 description 7
- 102000015799 Qa-SNARE Proteins Human genes 0.000 description 7
- 108010010469 Qa-SNARE Proteins Proteins 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 102000004183 Synaptosomal-Associated Protein 25 Human genes 0.000 description 5
- 108010057722 Synaptosomal-Associated Protein 25 Proteins 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000003518 presynaptic effect Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000009460 calcium influx Effects 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 2
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 2
- 101000944251 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) Calcium/calmodulin-dependent protein kinase cmkA Proteins 0.000 description 2
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 2
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 2
- 108010027023 Q-Type Calcium Channels Proteins 0.000 description 2
- 229930001406 Ryanodine Natural products 0.000 description 2
- 102000000583 SNARE Proteins Human genes 0.000 description 2
- 108010041948 SNARE Proteins Proteins 0.000 description 2
- HATRDXDCPOXQJX-UHFFFAOYSA-N Thapsigargin Natural products CCCCCCCC(=O)OC1C(OC(O)C(=C/C)C)C(=C2C3OC(=O)C(C)(O)C3(O)C(CC(C)(OC(=O)C)C12)OC(=O)CCC)C HATRDXDCPOXQJX-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 210000000782 cerebellar granule cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000000118 neural pathway Anatomy 0.000 description 2
- 230000010004 neural pathway Effects 0.000 description 2
- 230000003957 neurotransmitter release Effects 0.000 description 2
- 108010033421 omega-Agatoxin IVA Proteins 0.000 description 2
- JJSYXNQGLHBRRK-SFEDZAPPSA-N ryanodine Chemical compound O([C@@H]1[C@]([C@@]2([C@]3(O)[C@]45O[C@@]2(O)C[C@]([C@]4(CC[C@H](C)[C@H]5O)O)(C)[C@@]31O)C)(O)C(C)C)C(=O)C1=CC=CN1 JJSYXNQGLHBRRK-SFEDZAPPSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- IXFPJGBNCFXKPI-FSIHEZPISA-N thapsigargin Chemical compound CCCC(=O)O[C@H]1C[C@](C)(OC(C)=O)[C@H]2[C@H](OC(=O)CCCCCCC)[C@@H](OC(=O)C(\C)=C/C)C(C)=C2[C@@H]2OC(=O)[C@@](C)(O)[C@]21O IXFPJGBNCFXKPI-FSIHEZPISA-N 0.000 description 2
- NVVFOMZVLALQKT-JYRRICCISA-N ω-agatoxin iva Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCN)NC(=O)[C@H]1NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCSC)NC(=O)[C@@H](NC(=O)[C@H](CO)NC2=O)[C@@H](C)CC)[C@@H](C)O)CSSC[C@@H]2NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N2)NC3=O)CSSC[C@H]2C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=2C4=CC=CC=C4NC=2)C(=O)NCC(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N2CCC[C@H]2C(=O)N[C@H]3CSSC1 NVVFOMZVLALQKT-JYRRICCISA-N 0.000 description 2
- YJIYWYAMZFVECX-UHFFFAOYSA-N 2-[N-[2-(acetyloxymethoxy)-2-oxoethyl]-2-[2-[2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]anilino]acetic acid acetyloxymethyl ester Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O YJIYWYAMZFVECX-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 101000879393 Aplysia californica Synaptobrevin Proteins 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- 102000004657 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Human genes 0.000 description 1
- 108010003721 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Proteins 0.000 description 1
- 102000004646 Calcium-Calmodulin-Dependent Protein Kinase Type 4 Human genes 0.000 description 1
- 108010003613 Calcium-Calmodulin-Dependent Protein Kinase Type 4 Proteins 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101001131829 Homo sapiens P protein Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108090000699 N-Type Calcium Channels Proteins 0.000 description 1
- 102000004129 N-Type Calcium Channels Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- OKSSKVHGKYJNLL-UHFFFAOYSA-N Protogonyautoxin I Chemical compound N=C1NC(COC(=O)NS(O)(=O)=O)C2NC(=N)NC22C(O)(O)C(OS(O)(=O)=O)CN21 OKSSKVHGKYJNLL-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108090001076 Synaptophysin Proteins 0.000 description 1
- 102000004874 Synaptophysin Human genes 0.000 description 1
- GNJXVFXIDHCCKR-UHFFFAOYSA-N acetyloxymethyl 2-[[2-(acetyloxymethoxy)-2-oxoethyl]-[2-[2-[2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]ethoxy]ethoxy]ethyl]amino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)CCOCCOCCN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O GNJXVFXIDHCCKR-UHFFFAOYSA-N 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- -1 and of PKA Proteins 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940053031 botulinum toxin Drugs 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 150000001669 calcium Chemical class 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 description 1
- 229960004484 carbachol Drugs 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000047119 human OCA2 Human genes 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- PGHMRUGBZOYCAA-ADZNBVRBSA-N ionomycin Chemical compound O1[C@H](C[C@H](O)[C@H](C)[C@H](O)[C@H](C)/C=C/C[C@@H](C)C[C@@H](C)C(/O)=C/C(=O)[C@@H](C)C[C@@H](C)C[C@@H](CCC(O)=O)C)CC[C@@]1(C)[C@@H]1O[C@](C)([C@@H](C)O)CC1 PGHMRUGBZOYCAA-ADZNBVRBSA-N 0.000 description 1
- PGHMRUGBZOYCAA-UHFFFAOYSA-N ionomycin Natural products O1C(CC(O)C(C)C(O)C(C)C=CCC(C)CC(C)C(O)=CC(=O)C(C)CC(C)CC(CCC(O)=O)C)CCC1(C)C1OC(C)(C(C)O)CC1 PGHMRUGBZOYCAA-UHFFFAOYSA-N 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 210000000063 presynaptic terminal Anatomy 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 102000003137 synaptotagmin Human genes 0.000 description 1
- 108060008004 synaptotagmin Proteins 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- ATCJTYORYKLVIA-SRXJVYAUSA-N vamp regimen Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C(C45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 ATCJTYORYKLVIA-SRXJVYAUSA-N 0.000 description 1
- 230000011215 vesicle docking Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15909599P | 1999-10-13 | 1999-10-13 | |
| US159095P | 1999-10-13 | ||
| PCT/CA2000/001233 WO2001027630A2 (en) | 1999-10-13 | 2000-10-13 | Methods to identify compounds that modulate neuronal activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60024664D1 DE60024664D1 (de) | 2006-01-12 |
| DE60024664T2 true DE60024664T2 (de) | 2006-07-06 |
Family
ID=22571069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60024664T Expired - Fee Related DE60024664T2 (de) | 1999-10-13 | 2000-10-13 | Verfahren zur identifizierung von verbindungen, die die neuronale aktivität modulieren |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6531288B1 (enExample) |
| EP (1) | EP1230551B1 (enExample) |
| JP (1) | JP2003511087A (enExample) |
| AT (1) | ATE312350T1 (enExample) |
| AU (1) | AU7896700A (enExample) |
| CA (1) | CA2385907A1 (enExample) |
| DE (1) | DE60024664T2 (enExample) |
| ES (1) | ES2253263T3 (enExample) |
| WO (1) | WO2001027630A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2424269T3 (es) * | 2002-11-01 | 2013-09-30 | Iris International, Inc. | Inmuno-PCR sándwich por desplazamiento |
| US20050266524A1 (en) * | 2003-12-03 | 2005-12-01 | Bulla Lee A | Beta integrin gene and protein |
| JP5188808B2 (ja) * | 2004-11-03 | 2013-04-24 | アイリス モレキュラー ダイアグノスティクス， インコーポレイテッド | 同種の分析物検出 |
| PT1815028E (pt) * | 2004-11-03 | 2012-01-24 | Iris Molecular Diagnostics Inc | Microbolhas para separação por afinidade |
| US20090246781A1 (en) * | 2008-02-21 | 2009-10-01 | Robert Klem | Method for early determination of recurrence after therapy for prostate cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5874236A (en) | 1988-04-04 | 1999-02-23 | Sibia Neurosciences. Inc. | DNA encoding human calcium channel α-1A, β1, β-2, and β-4 subunits, and assays using cells that express the subunits |
| US5623051A (en) * | 1994-11-10 | 1997-04-22 | University Of Washington | Methods and compositions for screening for presynaptic calcium channel blockers |
| JPH09299092A (ja) * | 1996-03-12 | 1997-11-25 | Takeda Chem Ind Ltd | 新規タンパク質およびそのｄｎａ |
-
2000
- 2000-10-13 CA CA002385907A patent/CA2385907A1/en not_active Abandoned
- 2000-10-13 ES ES00969145T patent/ES2253263T3/es not_active Expired - Lifetime
- 2000-10-13 AU AU78967/00A patent/AU7896700A/en not_active Abandoned
- 2000-10-13 JP JP2001530589A patent/JP2003511087A/ja active Pending
- 2000-10-13 WO PCT/CA2000/001233 patent/WO2001027630A2/en not_active Ceased
- 2000-10-13 US US09/688,295 patent/US6531288B1/en not_active Expired - Fee Related
- 2000-10-13 EP EP00969145A patent/EP1230551B1/en not_active Expired - Lifetime
- 2000-10-13 AT AT00969145T patent/ATE312350T1/de not_active IP Right Cessation
- 2000-10-13 DE DE60024664T patent/DE60024664T2/de not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2003511087A (ja) | 2003-03-25 |
| WO2001027630A3 (en) | 2001-12-06 |
| ES2253263T3 (es) | 2006-06-01 |
| ATE312350T1 (de) | 2005-12-15 |
| AU7896700A (en) | 2001-04-23 |
| CA2385907A1 (en) | 2001-04-19 |
| US6531288B1 (en) | 2003-03-11 |
| WO2001027630A2 (en) | 2001-04-19 |
| EP1230551A2 (en) | 2002-08-14 |
| EP1230551B1 (en) | 2005-12-07 |
| DE60024664D1 (de) | 2006-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69434166T2 (de) | Menschliche metabotropische glutamatrezeptor untertype hmglur7 und verwandte dns-verbindungen | |
| DE69936453T2 (de) | Für einen g-protein gekoppelten rezeptor, der an der empfindungstransduktion beteiligt ist, kodierende nukleinsäuren | |
| De Paola et al. | AMPA receptors regulate dynamic equilibrium of presynaptic terminals in mature hippocampal networks | |
| Jenkins et al. | Ankyrin-G coordinates assembly of the spectrin-based membrane skeleton, voltage-gated sodium channels, and L1 CAMs at Purkinje neuron initial segments | |
| DE69116563T3 (de) | Durch protoonkogenischen Proteinkomplex AP-1 kontrollierte Verfahren | |
| Ullian et al. | Rapid synaptic transmission in the avian ciliary ganglion is mediated by two distinct classes of nicotinic receptors | |
| DE69434067T2 (de) | Menschliche neuronale nikotin-acetylcholin-rezeptor-verbindungen und methoden ihres einsatzes | |
| Nykjaer et al. | Sortilin is essential for proNGF-induced neuronal cell death | |
| Sachdev et al. | Role of the basal forebrain cholinergic projection in somatosensory cortical plasticity | |
| DE69431432T2 (de) | Untereinheiten von menschlichen n-methyl-d-aspartat rezeptoren, diese kodierende nukleinsäure und dessen verwendung | |
| DE60121346T2 (de) | Suppressor-Gen | |
| DE69534776T2 (de) | Klonierung und expression von einer acetylcholin-durchlässigen ionenkanälen rezeptor-untereinheit | |
| DE69836229T2 (de) | Zusammensetzungen von durch niedervolt aktivierten kalziumkanälen und verfahren | |
| DE60018085T2 (de) | Prozess zum Screening von Molekülen, die spezifisch an die NEP-Bindungsstelle des QHNPR-pentapeptides binden | |
| Kittler et al. | The dynamic synapse: molecular methods in ionotropic receptor biology | |
| DE4037837A1 (de) | Zellfreie rezeptorbindungsteste, ihre herstellung und verwendung | |
| Puente et al. | The transient receptor potential vanilloid-1 is localized at excitatory synapses in the mouse dentate gyrus | |
| WO2001009612A1 (de) | Modulatorische bindungsstelle an kaliumkanälen zum screening | |
| DE102005051789B4 (de) | Der Botulinus Neurotoxin A Proteinrezeptor und seine Anwendungen | |
| EP1049465A1 (de) | Verwendung von inhibitoren für die behandlung von rtk-überfunktions-bedingten störungen, insbesondere von krebs | |
| DE60027152T2 (de) | Verfahren zur detektion von antigenspezifischen t-zellen | |
| DE60115878T2 (de) | Schmerz signalisierende moleküle | |
| Zadeh et al. | Internalized Kv1. 5 traffics via Rab‐dependent pathways | |
| EP1537142B1 (de) | Akap18 delta, eine neue spleissvariante eines proteinkinase a-ankerproteins und verwendung dieser | |
| DE60024664T2 (de) | Verfahren zur identifizierung von verbindungen, die die neuronale aktivität modulieren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |